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ABSTRACT
A retrospective cohort analysis was performed to determine the impact of neutropenia on the outcome of hema-
topoietic cell transplantation (HSCT) in patients with myelodysplasia (MDS). Among 291 consecutive patients,
178 (61%) had absolute neutrophil counts (ANCs) \1500/mL and 113 (39%) had ANCs $1500/mL within
2 weeks before HSCT. Neutropenic patients more often had poor-risk karyotypes (34% versus 12%, P \
.0001) and high-risk International Prognostic Scoring System scores (37% veresus 18%, P 5 .0006). After
HSCT, the rate of infections caused by Gram-positive bacteria and invasive fungal infections was significantly
increased among neutropenic patients (rate ratio [RR] 1.77, P 5 .02 and RR 5 2.56, P 5 .03, respectively),
whereas infections caused by Gram-negative bacteria were not affected (RR 1.33, P5 .53). The hazards of non-
relapsemortality (NRM) (hazard ratio [HR]5 1.62 [1.1-2.4],P5 .01), overall mortality (HR5 1.55 [1.1-2.1],P5
0.007), and infection-related mortality (HR 5 2.22 [1.2-4.2], P 5 .01) were increased in neutropenic patients,
whereas relapse, engraftment, and graft-versus-host-disease were not affected. After adjusting for cytogenetic
risk and marrow myeloblast percentages, neutropenic patients remained at significant hazard for infection-re-
lated mortality (HR5 1.94 [1.0-3.8], P5 .05), but not for overall mortality or NRM.We propose that intensified
strategies to prevent infections should be implemented in MDS patients with preexisting neutropenia who un-
dergo HSCT.
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Neutropenia has been previously defined as an ab-
solute neutrophil count (ANC)\2 standard deviations
below the normal mean of the population, usually
\1500/mL. The actual numeric value of neutropenia
is dependent upon age, ethnic group, and other genetic
and environmental factors [1]. Neutropenia is a fre-
quent problem in patients with myelodysplastic syn-
dromes (MDS) and is either a primary result of
marrow failure or develops secondary to therapy.
Among the International Prognostic Scoring System(IPSS) cohort of 805 patients with primary MDS
who had ANC data available, 366 (46%) had ANCs
\1500/mL [2]. Patients with neutropenia have an in-
creased risk of developing infections, and the risk and
type of infections depend on the severity and duration
of neutropenia [3,4]. The ability to assess neutropenia
as an isolated risk factor inMDS is limited. TheWorld
Health Organization’s (WHO) diagnostic schemata
do not have a separate classification system based
solely upon the type of cytopenia(s) present [5].
Although the IPSS does score the number of cytope-
nias, it does not consider the type or the severity of799
800 B. L. Scott et al.cytopenias present [2]. Furthermore, patients with
MDS may have increased risks of infectious complica-
tions above and beyond the severity of neutropenia as
they can have both quantitative and qualitative defects
in neutrophil function [6]. Other investigators have
shown that neutropenic patients with a diagnosis of
MDS or acute myelogenous leukemia (AML) have in-
creased risks for invasive aspergillosis in comparison
to neutropenic patients without these disorders, thus
indicating that it is not only the development of neu-
tropenia but also the underlying cause that predis-
poses neutropenic patients to certain types of
infections [7]. In a cohort of 109 patients with MDS
who underwent hematopoietic stem cell transplanta-
tion (HSCT) at the Fred Hutchinson Cancer Re-
search Center (FHCRC), death from infectious
complications accounted for 53% of overall mortality
[8]. Preexisting neutropenia likely was a predisposing
factor. The increased rate of infection could be sec-
ondary to pretransplant colonization with bacterial
or fungal organisms, increased antibiotic resistance
secondary to increased use of pretransplant antibi-
otics, or because of sustained impairment of immune
functions following engraftment.
Given the current lack of information, we per-
formed a retrospective cohort analysis to characterize
the effects of pretransplant neutropenia on posttrans-
plant outcomes. Additionally, we were interested in
characterizing associations between neutropenia and
other known predictors of survival.
MATERIALS AND METHODS
We performed a retrospective cohort analysis of
results in 291 consecutive patients with a diagnosis of
MDS or AMLwithmultilineage dysplasia transformed
from a prior diagnosis of MDS (tAML). Chronic mye-
lomonocytic leukemia (CMML) patients were ex-
cluded from this analysis. All patients received their
allogeneic HSCTs between January 1994 and Decem-
ber 2003 at the FHCRC or the VA Puget Sound
Healthcare System. All patients were enrolled in insti-
tutional review board-approved protocols active at
time of enrollment. One hundred seventy-eight pa-
tients (61%) had ANCs\1500/mL (neutropenic co-
hort) and 113 (39%) had ANCs $1500/mL
(nonneutropenic cohort) within 2 weeks prior to
HSCT. Within the neutropenic cohort, there were
137 patients who had an ANC\1000/mL, and 86 pa-
tients who had an ANC\500/mL. Patients who re-
ceived growth factor therapy within 30 days prior to
the ANC measurement were excluded from this anal-
ysis. Patients who received chemotherapy or other cy-
toreductive therapy within 30 days prior to
measurement of the ANC were excluded because their
neutropenia may have been solely because of cytotox-
icity rather than their underlying disease. Thirty-threenonneutropenic patients and 32 neutropenic patients
received chemotherapy.30 days before measurement
of the ANC. In this small number of patients, the
median time from chemotherapy to measurement of
the ANC was 101 (range: 41-563) and 115 (range:
36-806) days for the nonneutropenic and neutropenic
cohorts, respectively. There were no substantial differ-
ences between these 2 groups in regard to distribution
by median follow-up, median age, sex, or etiology of
MDS/tAML (Table 1). Additionally, the distribution
by WHO diagnostic categories was similar between
the 2 groups. However, patients with neutropenia
were more likely to be in the IPSS high-risk group
(65% versus 17.7%, P5 .0006), and this was primarily
because of the presence of poor risk cytogenetics
(33.7% versus 12.4%, P\ .0001) [2].
All patients included in this analysis received mye-
loablative HSCT conditioning. In most patients this
consisted of busulfan (Bu), prescribed dose 16  1
mg/kg, dose adjusted to achieve target steady-state
levels of 600-900 ng/mL (tBu), plus cyclophospha-
mide (Cy), 2  60 mg/kg (Table 1) [8]. The remaining
patients were conditioned with tBu combined with
fludarabine, 4  30 mg/m2; Cy 2  60 mg/kg plus
12-14.4 Gy total body irradiation (TBI); tBu, Cy 2 
60 mg/kg plus 12 Gy TBI; Bu (7 mg/kg) plus 12 Gy
TBI; or myeloablative doses of radiolabeled I131
[9-13]. Stem cells were infused within 24 hours of
completion of TBI or within 36 to 48 hours of the
last dose of chemotherapy. All recipients received
T cell replete grafts. There were no differences be-
tween the 2 cohorts in regard to donor source, donor
HLA-matching, and stem cell source. ABO incompat-
ible grafts underwent red blood cell depletion or
plasma reduction depending on pretransplant recipi-
ent/donor ABO isoagglutinin titers.
The majority of the neutropenic patients (84%)
and nonneutropenic patients (70%) received intrave-
nous methotrexate (MTX) and cyclosporine (CsA)
for graft-versus-host disease (GVHD) prophylaxis
[14]. Acute GVHD (aGVHD) was diagnosed and
graded according to consensus criteria [15]. Chronic
GVHD (cGVHD) was diagnosed as clinically limited
or extensive (requiring immunosuppressive therapy)
using previously published criteria [16,17].
Infection Surveillance and Prophylaxis
All patients were monitored for the onset of infec-
tions during the first 100 days afterHSCT.Monitoring
included bacterial and fungal blood cultures and chest
radiographs when patients developed a fever
(.38.3C orally). Additionally, all patients receiving
$0.5 mg/kg of corticosteroid therapy were monitored
with weekly bacterial and fungal blood cultures and
chest radiographs. For Pneumocystis jiroveci prophylaxis
all patients received trimethoprim/sulfamethoxasole as
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or atovaquone as third-line therapy from time of en-
graftment until 6 months after HSCT or until 6 weeks
after all immunosuppressive medications had been dis-
continued. All patients received fluconazole or itraco-
nazole for prevention of candidiasis from time of
conditioning until day 75 afterHSCT [19]. Prophylac-
tic systemic antibiotics with levofloxacin or ceftazidime
Table 1. Patient, Disease, and Transplant Characteristics
No. of Patients (%)
Characteristic
ANC
\1500/mL
ANC
$1500/mL
No. of patients 178 113
Age years, median (range) 49 (3-66) 45 (1-66)
Sex, M/F, no. of patients 103/75 63/50
Follow-up years, median (range) 5 (0.1-12) 6.3 (1.2-12)
Time from diagnosis to transplant
days, median (range)
223 (51-4867) 244 (22-3150)
WHO stage, no. of patients (%)
\5% marrow myeloblasts; no
peripheral blasts
66 (37) 48 (42)
RA 21 15
RARS/RCMD-RS 4 4
RCMD 28 14
MDS-U 5 5
5q- 8 10
RAEB-1 23 (13) 15 (13)
RAEB-2 27 (15) 12 (11)
tAML 62 (35) 38 (34)
IPSS risk group, no. of patients (%)
Low 11 (6) 22 (19)
Intermediate-1 46 (26) 41 (36)
Intermediate-2 56 (31) 30 (27)
High 65 (37) 20 (18)
Cytogenetic risk group, no. of patients (%)
Good 87 (49) 71 (63)
Intermediate 31 (17) 28 (25)
Poor 60 (34) 14 (12)
Related donor 93 (52) 57 (50)
HLA-identical sibling 79 (44) 46 (40)
HLA-mismatched family member 10 (6) 7 (6)
HLA-matched family member 4 (2) 2 (2)
Syngeneic 0 2 (2)
Unrelated donor 85 (48) 56 (50)
HLA-matched 55 (31) 42 (37)
HLA-mismatched 30 (17) 14 (13)
Source of stem cells
Peripheral blood 92 (52) 51 (45)
Marrow 86 (48) 61 (54)
Cord blood 0 1 (1)
Conditioning regimen
tBuCy 99 (56) 74 (65)
BuFlu 13 (7) 4 (4)
BuTBI 35 (20) 10 (9)
CyTBI 28 (15) 22 (19)
I-131 3 (2) 2 (2)
MelBu 0 1 (1)
Bu indicates busulfan; CSP, cyclosporine; Cy, cyclophosphamide;
FK506, tacrolimus; Flu, fludarabine; I-131, radioiodine-labeled
monoclonal antibody; IPSS, International Prognostic Scoring
System; MMF, mycophenolate mofetil; MTX, methotrexate;
TBI, total body irradiation;WHO,World Health Organization.[20] were initiated in all patients when their ANCs fell
below 500/mL.
Definitions of Endpoints
The day of onset of infection was defined as the day
the diagnostic test was performed [21]. Invasive fungal
infections were defined by the National Institutes of
Health Mycosis Study Group/European Organization
for Research and Treatment of Cancer consensus cri-
teria [22]. Bacterial infections were defined as positive
blood, bronchial lavage (lower respiratory tract), or
urine cultures. The day of engraftment was defined
as the first of 3 consecutive days on which the ANC re-
mained .500/mL. Evidence of graft rejection was
sought in patients who failed to reach ANCs of 500/
mL by day 28, and in patients with sustained declines
in counts after initial recovery. All patients hadmarrow
evaluations scheduled on days 28, 56, 84 (63 days), and
1 year after HSCT, and subsequently as clinically
indicated. Relapse was defined as posttransplant reap-
pearance of dysplastic cells by flow cytometry, mor-
phologic evidence of dysplastic myeloblasts, or the
reappearance of cytogenetic abnormalities identified
pretransplant [23,24]. In patients with morphologic,
hematologic, or cytogenetic evidence of relapse, re-
lapse rather than graft rejection was considered to be
the cause of failed engraftment. In patients with re-
lapse, relapse was listed as the primary cause of death
regardless of other associated events. In patients with
GVHD requiring immunosuppressive therapy who
subsequently died with infections, GVHDwas consid-
ered the cause of death. Multiorgan failure was identi-
fied as the cause of death when it occurred in the
absence of relapse and was thought not to be primarily
because of preceding GVHD or infection. Graft rejec-
tion was considered the cause of death if patients had
documented loss of graft function after day 28 post-
transplant without evidence of relapse or GVHD. In-
fections were considered causes of death when they
occurred in the absence of GVHD, relapse, graft fail-
ure, and graft rejection. The coding of death was per-
formed by reviewing autopsy and other medical
documents by a single investigator (B.L.S.) who was
blinded to the cohort assignment.
Statistical Analysis
Results were analyzed as ofDecember 2006.Overall
survival (OS) and progression-free survival were esti-
mated using the Kaplan-Meier method. Cumulative
incidence curves for relapse-related mortality, nonre-
lapse mortality (NRM), and infection-related mortality
wereestimated according tomethodsdescribedbyGoo-
ley et al. [25]. Deaths were treated as competing events
in the analyses of engraftment, GVHD, and progres-
sion. Unadjusted and adjusted rate ratios for infection
during the first 100 days posttransplant were estimated
802 B. L. Scott et al.using Poisson regression. Rates of bacterial infections
were adjusted by use of TBI and cytomegalovirus
(CMV) recipient serostatus 1 versus 2 [26]. Rates of
invasive fungal infections were adjusted by age .40
years and matched related donor versus other donors
[27]. Increased risk of bacterial and fungal infections
by degree of neutropenia was evaluated using a test for
trend across the neutropenia categories 1500 to 1000,
1000 to 500, and\500.Unadjusted and adjusted hazard
ratioswere estimatedusingproportional hazards regres-
sionmodels.Given the increased prevalence of poor risk
cytogenetics among the neutropenic cohort, adjust-
ments weremade for cytogenetic status (good, interme-
diate, and poor risk). Additionally, the analyses were
adjusted for marrow myeloblast percentages (\5, 5-9,
10-19, 20-29, and $30). We did not adjust for IPSS
classification because the IPSS includes neutropenia
within the number of blood cytopenias. There were no
differences between the 2 cohorts in regard to other
potential confounding variables such as age, etiology,
GVHD prophylaxis, stem cell source, donor type, and
conditioning regimen.
RESULTS
Among the 178 patients with pretransplant neutro-
penia, 7 (4%) died before day 28 without evidence of
GVHD and were considered not evaluable for engraft-
ment. An additional 5 patients (3%) died with graft fail-
ure or graft rejection at 38 to 343 days.Themedian time
to neutrophil engraftment in the remaining 166 patients
was 17 (range: 10-31) days. There were no differences
observed in median engraftment by severity of neutro-
penia (ANC 1500-1000/mL, 1000-500/mL, and\500/
mL).Among the 113patientswithout pretransplant neu-
tropenia, 6 patients (5%) died before day 28 without
evidence of GVHD and were considered not evaluable
for engraftment.Onepatient (1%)diedwithgraft failure
at 46 days. The median time to engraftment in the
remaining 106 patients was 17 (range: 10-33) days.
The cumulative incidences of grades II-IV GVHD
were not different between the neutropenic (80%) and
the nonneutropenic cohorts (76%) (P5 .42), nor were
the cumulative incidences of grades III-IV GVHD
(32% versus 24%, P 5 .15). The 3-year OS was
39.7% for the neutropenic cohort and 55.7% for the
nonneutropenic cohort (Figure 1). The decreased OS
observed in the neutropenic cohort was chiefly second-
ary to differences in NRM. The neutropenic cohort
had higher incidences of NRM than the nonneutro-
penic cohort, 24.4% versus 14.3% and 39.6% versus
26.7% at day 100 and 1 year, respectively (Figure 2).
Specifically, the neutropenic cohort had an increased
incidence of infection-related mortality at 3 years in
comparison to the nonneutropenic cohort (26% versus
12.3%) (Figure 3). The 3-year cumulative incidencesof relapse were similar between the 2 cohorts, 20.3%
and 19.3%, respectively.
The neutropenic cohort had significantly higher
hazards for overall mortality, NRM, and infection-re-
lated mortality (Table 2); however, patients in this
cohort were also more likely to have poor risk cytoge-
netics and an overall higher IPSS classification.
Therefore, adjusted analyses were performed using
cytogenetic risk and marrow myeloblast percentages
as detailed in the statistical section. Following adjust-
ment, the neutropenic cohort no longer had signifi-
cantly higher hazards for OS or NRM; however,
the hazard for infection-related mortality remained
significantly higher.
We also evaluated whether the hazards of NRM,
mortality, and relapse increased with increasing de-
grees of neutropenia. To that end, neutropenic pa-
tients were compared to nonneutropenic patients
using ANC cutoffs of 1000 to 1500/mL (n 5 41), 500
to 1000/mL (n 5 51), and\500/mL (n 5 86). There
was no increased risk of poor HSCT outcomes with
increasing severity of neutropenia (data not shown).
Figure 1.OS among neutropenic (ANC\1500/mL) and nonneutro-
penic (ANC $1500/mL) patients. HR 5 1.55 (1.1-2.1), P 5 .007.
Figure 2. NRM among neutropenic and nonneutropenic patients.
HR 5 1.62 (1.1-2.4), P 5 .01.
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fection-related mortality; however, the distribution
was highly skewed toward a short time interval from
diagnosis to HSCT: 75% of the patients in both neu-
tropenic and nonneutropenic cohorts were trans-
planted within 500 days of diagnosis.
Types of Posttransplant Infections
Overall, the neutropenic cohort had significantly
increased rates of bacterial and fungal infections in
comparison to nonneutropenic patients within the
first 100 days after HSCT (relative risk [RR] 5 1.59,
P5 .001 and RR5 2.89, P5 .01, respectively) (Table
2). Most fungal infections were caused by the Aspergil-
lus species (27 of 32), and the remaining fungal infec-
tions were because of Candida glabrata (2 of 32) and
mucor (3 of 32). The propensity for neutropenic pa-
Figure 3. Infection-related mortality among neutropenic and non-
neutropenic patients. HR 5 2.22 (1.2-4.2), P 5 .01.tients to develop bacterial infections varied by type
of organism. There was an increase in the rate of in-
fections with Gram-positive organisms (RR 5 1.77,
P 5 .02), but not with Gram-negative rods. The in-
creased rate of fungal and gram positive bacterial in-
fections among the neutropenic patients was most
prominent more than 60 days after HSCT (Figure 4).
The rate ratio for fungal infections remained un-
changed after adjustment for aGVHD grades II-IV
(RR 5 2.76, 95% confidence interval [CI] 1.1-6.7, P
5 .01), indicating there was no evidence of confound-
ing by aGVHD. There was no association between
pretransplant colonization with bacteria or fungal or-
ganisms and the subsequent development of bacterial
or invasive fungal infections; however, these data are
limited by the fact that no routine surveillance for col-
onization was employed. The increasing levels of neu-
tropenia (ANC 1500-1000/mL, 1000-500/mL, and
\500/mL) had no further significant impact on an in-
creased risk of fungal and bacterial infections using
a test for trend (data not shown).
Effects of Single Lineage Pretransplant Cytopenias
Among the patients evaluated in these analyses,
there were 16 (4.6%) with isolated neutropenia
(ANC\1500/mL), 22 (6.3%) with isolated thrombo-
cytopenia (platelet count \100,000/mL), and 25
(7.1%) with isolated anemia (Hgb\10 g/dL). Given
the inferior HSCT outcomes observed with neutrope-
nia, we were interested in determining whether iso-
lated neutropenia was associated with worse HSCT
outcomes than observed in patients with other single
lineage cytopenias. Patients with each of the isolated
cytopenias were compared to patients withoutTable 2. Hazard Ratios and Rate Ratios Comparing Neutropenic and Nonneutropenic Cohorts
ANC\1500/mL ANC\1500/mL Adjusted
Outcomes HR (95% CI) P-value HR (95% CI)* P-value*
Overall mortality 1.55 (1.1-2.1) .007 1.19 (0.8-1.7) .34
Nonrelapse mortality (NRM) 1.62 (1.1-2.4) .01 1.31 (0.9-2.0) .2
Relapse 1.31 (0.8-2.3) .33 0.96 (0.5-1.8) .9
Infection-related mortality 2.22 (1.2-4.2) .01 1.94 (1.0-3.8) .05
RR (95% CI) P-value RR (95% CI)† P-value†
Bacterial infection‡ (223 in 60 pts) 1.59 (1.2-2.1) .001 1.42 (1.1-1.9) .01
Gram-negative rods (21 in 11 pts) 1.33 (0.5-3.3) .53 1.27 (0.5-3.2) .6
Gram-positive organisms§ (84 in 37 pts) 1.77 (1.1-2.9) .02 1.51 (0.9-2.1) .09
Coagulase-negative staph (102 in 40 pts) 1.46 (1.0-2.2) .07 1.35 (0.9-2.1) .16
Bacillus and Corynebacterium (8 in 6 pts) ////¶ .004 N/A N/A
Fungal infection‡ (32 in 31 pts) 2.89 (1.2-7.0) .01 2.89 (1.2-7.0) .01
HR indicates hazard rate ratio; RR, rate ratio.
*Adjusted for cytogenetic risk group and bone marrow myeloblast percentage.
†Adjusted for TBI conditioning and CMV recipient1 versus2 for bacterial infections or HLA-matched related donor versus other and age#
or .40 years for fungal infections.
‡All infection rates estimated using Poisson regression, truncated at death or day 100.
§Excluding Coagulase-negative staph, Bacillus and Corynebacterium.
¶All Bacillus and Corynebacterium infections occurred in neutropenic patients.
804 B. L. Scott et al.cytopenias (n5 32) using proportional hazards regres-
sion analysis and adjusted for cytogenetic risk andmar-
row myeloblast percentages (Table 3). Although the
numbers of patients within the subgroups were small,
there was a strong trend for an increased risk of worse
outcomes among patients with isolated neutropenia
and thrombocytopenia.
Figure 4. (A) Percent of invasive fungal infections among neutro-
penic and nonneutropenic patients from day 0 to day 100 posttrans-
plant. HR 5 2.89 (1.2-7.0), P 5 .01. (B) Percent of Gram-positive
bacterial infections among neutropenic and nonneutropenic patients
from day 0 to day 100 posttransplant. HR5 1.77 (1.1-2.9), P5 .02.DISCUSSION
For the study interval January 1994 to December
2006, 61% of patients with MDS and tAML met the
definition of neutropenia (ANC\1500/mL). The neu-
tropenia present in this patient population was second-
ary to the underlying disease rather than the receipt of
chemotherapy or alternative treatments. Neutropenia
was associated with pretransplant poor-risk cytogenet-
ics and a high IPSS classification, but not a higher mar-
row myeloblast percentage. However, a limitation of
the present analysis was that only HSCT patients
were included, and therefore, the correlation of neu-
tropenia and poor-risk cytogenetics may be because
of a referral bias. Biologically, an association of poor-
risk cytogenetics with an overall decrease in marrow
function in MDS patients appears plausible, but this
possibility has not been examined systematically.
Pretransplant neutropenia was associated with sig-
nificantly increased hazards of NRM, overall mortal-
ity, and infection-related mortality. Of note, the
hazard did not increase significantly with the severity
of neutropenia. There may be a critical level of neutro-
penia combined with intrinsic abnormalities in the
neutrophils that confers the increased risk of infectious
complications; therefore, increasing levels of neutro-
penia did not result in increased risk of infectious com-
plications. However, there were few patients in this
subgroup analysis, and it is possible that we were not
able to detect a difference because of lack of power.
Neutropenic patients were not found to be at an in-
creased risk of relapse-related mortality despite ad-
verse factors such as poor risk cytogenetics and
increased IPSS scores. The increased rate of earlier
NRM may have removed the neutropenic patients
from a later risk of relapse. Following adjustment for
IPSS cytogenetic classification andmarrowmyeloblast
percentage, the neutropenic cohort no longer showed
a significantly increased hazard for overall mortality
and NRM, but the increased hazard for infection-
related mortality remained significant.
Overall, neutropenic patients were at an increased
risk of developing bacterial and invasive fungal infec-
tions in comparison to nonneutropenic patients. TheTable 3. Hazard Rate Ratios* Comparing Isolated Cytopenic Patients to Patients without Any Cytopenias (n 5 32)
ANC\1500/mL n516 Platelets\100,000/mL n 5 22 Hgb\10 g/dL n 5 25
Outcomes HR (95% CI) P-value HR (95% CI) P-value HR (95% CI) P-value
Overall mortality 2.39 (0.9-6.1) .07 2.25 (0.9-5.6) .08 1.25 (0.5-2.9) .6
NRM 2.96 (1-8.6) .05 3.49 (1.1-11) .03 1.52 (0.5-4.6) .45
Relapse /////† .08 0.46 (0.1-3.1) .43 1.09 (0.3-4.3) .9
Infection related 8.19 (0.8-86) .08 6.22 (0.6-66) .13 5.67 (0.6-54) .13
HR indicates hazard ratio; CI, confidence interval; ANC, absolute neutrophil count.
*Adjusted for cytogenetic risk group and bone marrow myeloblast percentage.
†No events occurred in the isolated neutropenic cohort.
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neutropenic and nonneutropenic patients. Further-
more, there was no difference in median engraftment
with increasing severity of neutropenia. Therefore, it
is unlikely that the difference in infection rates were
secondary to differences in engraftment. The types
of bacterial infections that developed in neutropenic
patients tended to be different from those in nonneu-
tropenic patients. Neutropenic patients more fre-
quently developed infections with Gram-positive
organisms rather than Gram-negative organisms,
indicative of a possible increased risk of catheter-
associated infections in neutropenic patients in com-
parison to nonneutropenic patients. The increased
rate of fungal and bacterial infections among patients
with pretransplant neutropenia was most prominent
after day 60 posttransplant, thereby indicating a possi-
ble multiplicative association between pretransplant
neutropenia and therapy for GVHD (generally with
steroids) with invasive fungal infections.
The time from diagnosis to HSCT in neutropenic
patients was thought to be an important predictor of
NRM and specifically infection-related mortality.
With increased time, it was suspected that increased
colonization would result in increased rates of death
from infection in the neutropenic cohort compared
to the nonneutropenic cohort. However, as specified
in the results section the time from diagnosis to
HSCT was highly skewed toward a short time interval
for both cohorts (\500 days), and we were not able to
adequately address this issue because of a lack of dis-
cordance between the neutropenic and nonneutro-
penic cohorts. Because we studied only patients who
underwent HSCT, we cannot comment on outcome
for neutropenic patients treated with other modalities.
Neutropenic patients who had a long delay between
diagnosis and consideration of HSCTmay have devel-
oped serious infectious complications that precluded
the option of and referral for HSCT.
In summary, neutropenia in patients with MDS
was associated with poor-risk cytogenetic features
and with an increased hazard of overall mortality,
NRM, and infection-related mortality following
HSCT. After adjusting for cytogenetics and marrow
myeloblast percentage, neutropenia remained signifi-
cantly associated with an increased hazard of infec-
tion-related mortality. The numbers of patients were
too small to evaluate the impact of isolated cytopenias
in this analysis, although there was a suggestion that
patients with isolated neutropenia or thrombocytope-
nia fared less well than patients with isolated anemia.
We observed increased rates of fungal and Gram-pos-
itive bacterial infections in the neutropenic cohort.
The primary disadvantage among neutropenic
patients was infection-related mortality. Therefore,
increased surveillance and more intensive infectionprophylaxis may be warranted in neutropenic MDS
patients who undergo HSCT.
ACKNOWLEDGMENTS
This work was supported in part by grants
HL084054, HL36444, CA18029, CA15704, and
HL82941 from the National Institutes of Health, Be-
thesda, MD. We thank the HSCT teams at the Fred
Hutchinson Cancer Research Center and the Seattle
VA Puget Sound Health Care System for their contri-
butions, all patients for their participation in these trials,
Joanne Greene and Franchesca Nguyen for maintain-
ing the patient database, and Bonnie Larson andHelen
Crawford for help with manuscript preparation.
REFERENCES
1. Dale DC. Neutropenia and neutrophilia. In: Lichtman MA,
Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT, eds.
Williams Hematology. New York: McGraw-Hill; 2006. p. 907-919.
2. Greenberg P, Cox C, LeBeau MM, et al. International scoring
system for evaluating prognosis in myelodysplastic syndromes
(erratum appears in Blood 1998;91:1100). Blood. 1997;89:
2079-2088.
3. Engels EA, Ellis CA, Supran SE, et al. Early infection in bone
marrow transplantation: quantitative study of clinical factors
that affect risk. Clin Infect Dis. 1999;28:256-266.
4. Viscoli C, Varnier O,Machetti M. Infections in patients with fe-
brile neutropenia: epidemiology, microbiology, and risk stratifi-
cation. Clin Infect Dis. 2005;40(Suppl 4):S240-S245.
5. Vardiman JW, Harris NL, Brunning RD. The World Health
Organization (WHO) classification of the myeloid neoplasms.
Blood. 2002;100:2292-2302.
6. Yamaguchi N, Ito Y, Ohyashiki K. Increased intracellular activ-
ity of matrix metalloproteinases in neutrophils may be associated
with delayed healing of infection without neutropenia in myelo-
dysplastic syndromes. Ann Hematol. 2005;84:383-388.
7. Mu¨hlemann K, Wenger C, Zenha¨usern R, Ta¨uber MG. Risk
factors for invasive aspergillosis in neutropenic patients with
hematologic malignancies. Leukemia. 2005;19:545-550.
8. DeegHJ, Storer B, Slattery JT, et al. Conditioning with targeted
busulfan and cyclophosphamide for hemopoietic stem cell trans-
plantation from related and unrelated donors in patients with
myelodysplastic syndrome. Blood. 2002;100:1201-1207.
9. Anderson JE, Appelbaum FR, Fisher LD, et al. Allogeneic bone
marrow transplantation for 93 patients with myelodysplastic
syndrome. Blood. 1993;82:677-681.
10. Anderson JE, Appelbaum FR, Schoch G, et al. Allogeneic mar-
row transplantation for myelodysplastic syndrome with ad-
vanced disease morphology: a phase II study of busulfan,
cyclophosphamide, and total-body irradiation and analysis of
prognostic factors. J Clin Oncol. 1996;14:220-226.
11. Jurado M, Deeg HJ, Storer B, et al. Hematopoietic stem cell
transplantation for advanced myelodysplastic syndrome after
conditioning with busulfan and fractionated total body irradia-
tion is associated with low relapse rate but considerable nonre-
lapse mortality. Biol Blood Marrow Transplant. 2002;8:161-169.
12. Bornhauser M, Storer B, Slattery JT, et al. Conditioning with
fludarabine and targeted busulfan before transplantation of al-
logeneic hematopoietic stem cells. Blood. 2002;100(Part 1):
213a.
806 B. L. Scott et al.13. Pagel JM, Appelbaum FR, Eary JF, et al. 131I-anti-CD45 anti-
body plus busulfan and cyclophosphamide before allogeneic he-
matopoietic cell transplantation for treatment of acute myeloid
leukemia in first remission. Blood. 2006;107:2184-2191.
14. Storb R, Deeg HJ, Whitehead J, et al. Methotrexate and cyclo-
sporine compared with cyclosporine alone for prophylaxis of
acute graft versus host disease after marrow transplantation for
leukemia. N Engl J Med. 1986;314:729-735.
15. PrzepiorkaD,WeisdorfD,Martin P, et al. 1994Consensus con-
ference on acuteGVHDgrading.BoneMarrow Transplant. 1995;
15:825-828.
16. Sullivan KM, Shulman HM, Storb R, et al. Chronic graft-ver-
sus-host disease in 52 patients: adverse natural course and suc-
cessful treatment with combination immunosuppression. Blood.
1981;57:267-276.
17. Flowers MED, Traina F, Storer B, et al. Serious graft-versus-host
diseaseafterhematopoietic cell transplantation followingnonmye-
loablative conditioning [erratum appears in Bone Marrow Trans-
plant. 2005;35:535]. Bone Marrow Transplant. 2005;35:277-282.
18. SangioloD, Storer B,NashR, et al. Toxicity and efficacy of daily
Dapsone as Pneumocystis jiroveci prophylaxis after hematopoietic
stem cell transplantation: a case-control study. Biol BloodMarrow
Transplant. 2005;11:521-529.
19. Marr KA, Crippa F, Leisenring W, et al. Itraconazole versus
fluconazole for prevention of fungal infections in allogeneic
stem cell transplant patients. Blood. 2004;103:1527-1533.
20. HakkiM, Limaye AP, KimHW,KirbyKA, Corey L, BoeckhM.
Invasive Pseudomonas aeruginosa infections: high rate of recur-rence and mortality after hematopoietic cell transplantation.
Bone Marrow Transplant. 2007;39:687-693.
21. Crippa F, Holmberg L, Carter RA, et al. Infectious complica-
tions after autologous CD34-selected peripheral blood stem
cell transplantation. Biol Blood Marrow Transplant. 2002;8:
281-289.
22. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic in-
vasive fungal infections in immunocompromised patients with
cancer and hematopoietic stem cell transplants: an international
consensus. Clin Infect Dis. 2002;34:7-14.
23. Deeg HJ, ShulmanHM, Anderson JE, et al. Allogeneic and syn-
geneic marrow transplantation for myelodysplastic syndrome in
patients 55 to 66 years of age. Blood. 2000;95:1188-1194.
24. Sievers EL, Lange BJ, Buckley JD, et al. Prediction of relapse of
pediatric acute myeloid leukemia by use of multidimensional
flow cytometry. J Natl Cancer Inst. 1996;88:1483-1488.
25. Gooley TA, Martin PJ, Fisher LD, Pettinger M. Simulation as
a design tool for phase I/II clinical trials: an example from bone
marrow transplantation. Controlled Clin Trials. 1994;15:450-462.
26. Chien JW, Boeckh M, Hansen JA, Clark JG. Lipopolysaccha-
ride binding protein promoter variants influence the risk for
gram-negative bacteremia and mortality after allogeneic hema-
topoietic cell transplantation. Blood; prepublished online
December 3, 2007; DOI 10.1182/blood-2007-09-101709.
27. Marr KA, Carter RA, Boeckh M, Martin P, Corey L. Inva-
sive aspergillosis in allogeneic stem cell transplant recipients:
changes in epidemiology and risk factors. Blood. 2002;100:
4358-4366.
